Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors

Published by: Decision Resources

Published: Feb. 14, 2008 - 21 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Current Treatments for Type 2 Diabetes

Metformin

Sulfonylureas

Peroxisome Proliferator-Activated Receptor-Gamma Agonists

Glucagon-Like Peptide-1 Analogues

The Type 2 Diabetes Market

2007 Sales and Prescriptions

Uptake of New Agents in the Type 2 Diabetes Market

PPAR-ã Agonists

Byetta

Januvia—First in Class

Mechanism of Action

Clinical Trial Results

Januvia’s Uptake in the Market

Emerging Competition

Novartis’s Galvus

Takeda’s Alogliptin

Bristol-Myers Squibb/AstraZeneca’s Saxagliptin

Early-Stage DPP-IV Inhibitors

Outlook for DPP-IV Inhibitors

Tables:

1. Worldwide Sales of Agents Commonly Prescribed to Treat Type 2 Diabetes, 2007

2. Emerging Glucagon-Like Peptide 1 Analogues and Peroxisome Proliferator-Activated Receptor Agonists

3. Physiological Functions of the Incretins GLP-1 and GIP

Figures:

1. Typical Decision Tree for Type 2 Diabetes, 2008

2. Market Share of Drug Classes to Treat Type 2 Diabetes, 2007

3. Sales of Newly Launched Agents to Treat Type 2 Diabetes, 2000-2006

4. Volume Share of Drug Classes Used to Treat Type 2 Diabetes, First Half of 2007

5. U.S. Sales of Januvia by Quarter, 2006-2007

Abstract

Introduction

Despite the variety of efficacious oral antidiabetics available to treat type 2 diabetes—many of them available generically—the unmet need in this disease remains high. In October 2006, the launch of Merck’s Januvia (sitagliptin) introduced to the U.S. market the newest class of agents to treat this disease, the dipeptidyl peptidase-IV (DPP-IV) inhibitors, which enjoy several advantages over their competitors. In this report, we review current and emerging treatment options for type 2 diabetes and examine the market, providing data on the uptake of novel branded agents over the last five years. We focus particularly on Januvia, its current clinical trial data, and its market uptake since launch; on Novartis’s Galvus and Takeda’s alogliptin, likely to be Januvia’s most direct competitor; and on the market outlook for the DPP-IV inhibitor class.

Get the Answers You Need to Shape Your Strategy
  • The high level of unmet needs in type 2 diabetes offers significant opportunity for novel agents even at premium prices and despite generic competition. What are the greatest unmet needs in treatment of type 2 diabetes? Are any emerging therapies likely to fulfill these needs? What benefits do current therapies offer diabetic patients, and what are their drawbacks? Why will metformin continue to be physicians’ first choice for first-line therapy?
  • The DPP-IV inhibitors offer several advantages over currently available therapies for type 2 diabetes. In what way are they superior to existing therapies? What unmet needs can these agents fulfill? What drawbacks may hinder physician uptake of the DPP-IV inhibitors? How are physicians likely to use these agents? Will they supplant any of the current leading therapies? Which companies are leading the development of DPP-IV inhibitors? What is the market outlook for the DPP-IV inhibitors?
Scope
  • Current therapies, type 2 diabetes: Metformin (biguanide), sulfonylureas, peroxisome proliferator-activated receptor-gamma agonists (Actos, Avandia), glucagon-like peptide-1 analogues (Byetta), advantages, drawbacks, physician preferences.
  • Type 2 diabetes market: 2007 sales and prescriptions, market leaders, uptake of emerging agents.
  • Dipeptidyl peptidase-IV (DPP-IV) inhibitors: Januvia (sitagliptin, Merck), Galvus (vildagliptin, Novartis), alogliptin (Takeda), and saxagliptin (BMS, AstraZeneca), mechanism of action, clinical trials data, market uptake, sales and prescriptions, market outlook. Galvus (vildagliptin, Novartis)— estimated launch date, clinical trials data. Market outlook for DPP-IV inhibitors.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008